In March 2025, the company announced new plans for a direct-to-purchaser offering of its Wegovy weight loss drug. The company set up a different pharmacy, called NovoCare, which would demand clients $499 monthly for entry to the drug, under 50 percent the expense of the drug by other pharmaceutical distribution networks.[fifty three]A weight loss p